findmyKOL
Clinical trialNCT00228592TerminatedPhase 2Interventional

HepeX-B in Post Hepatic Allografts for Treatment of End Stage Liver Disease Due to Hepatitis B Infection

SponsorCubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Hepatitis BLiver Transplantation
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to compare the use of HepeX-B versus HBIg, two anti-viral drugs, in patients who have received liver transplants due to liver failure caused by Hepatitis B infection. Patients will be evaluated over a 6 month to 1.5 year period to evaluate whether or not the drugs prevent the Hepatitis B virus from infecting the new liver.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

20 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

France
  • Centre Hepato-Biliaire Hospital Paul Brousse

    Paris, France

Germany
  • Humbolt University Virchow Clinic Dept. Viceral and Transplant Surgery

    Berlin, Germany

Israel
  • Hadassah University Hospital

    Jerusalem, Israel

  • Rabin Medical Center

    Petah Tikva, Israel

  • Tel-Aviv Sourasky Medical Center

    Tel Aviv, Israel

New Zealand
  • Auckland City Hospital

    Auckland, New Zealand

Spain
  • Hospital la Fe Servicio de Medicina Degestiva

    Valencia, Spain

United Kingdom
  • Royal Free Hospital

    London, United Kingdom

United States
  • Ucla

    Los Angeles, California, United States

  • California Pacific Medical Center

    San Francisco, California, United States

  • Ucsf

    San Francisco, California, United States

  • Mayo Clinic

    Rochester, Minnesota, United States

  • University of Nebraska

    Omaha, Nebraska, United States

  • Mt. Sinai

    New York, New York, United States

  • University of North Carolina

    Chapel Hill, North Carolina, United States

  • University of Cincinnati Medical Center

    Cincinnati, Ohio, United States

  • University of Pennsylvania Health System

    Philadelphia, Pennsylvania, United States

  • University of Virginia

    Charlottesville, Virginia, United States

  • Metropolitan Liver Diseases/gastroenterology Center

    Fairfax, Virginia, United States

  • Virginia Commonwealth University Health System

    Richmond, Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Hepatitis B immune globulinHepeX-B
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
—
Primary completion
—
Completion
31 Aug 2005
Last update posted
13 Feb 2007
Registered enrollment
—
Registry id
NCT00228592
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.